Glucotrack to File for FDA Exemption Based on 2025 Milestones

40 second read

By Karen Roman

GlucoTrack, Inc. (Nasdaq: GCTK) said it will request an Investigational Device Exemption (IDE) from the FDA for its continuous blood glucose monitoring technology.

This submission follows the completion of clinical trials in Brazil and Australia, and is set to be completed during the second quarter of 2026, the company stated.

“With trial infrastructure in place and product enhancements completed, we are prepared to initiate the study, pending FDA approval,” said Paul V. Goode, PhD, Glucotrack’s President and CEO.

READ MORE